- £56.72m
- £52.42m
- £4.00m
REG - Creo Medical Group - Speedboat® UltraSlim: US FDA Clearance
AnnouncementREG - Creo Medical Group - SB UltraSlim: EU launch accelerated by 18 months
AnnouncementREG - Creo Medical Group - Change of Nominated Adviser and Joint Broker
AnnouncementRCS - Creo Medical Group - Investor Presentation
AnnouncementREG - Creo Medical Group - Half-year Report
AnnouncementREG - Creo Medical Group - Notice of Results
AnnouncementRCS - Creo Medical Group - Royal Oldham SSD service update
AnnouncementREG - Creo Medical Group - Half Year Trading Update
AnnouncementREG - Creo Medical Group - Total Voting Rights
AnnouncementREG - AIM - AIM Notice - 27/07/2023
AnnouncementREG - Creo Medical Group - Award of Shares under Share Incentive Plan
AnnouncementREG - AIM - AIM Notice - 12/07/2023
AnnouncementREG - Creo Medical Group - Issue of Equity and TVR
AnnouncementREG - Creo Medical Group - Result of AGM
AnnouncementREG - Creo Medical Group - AGM Statement & Directorate Succession Planning
AnnouncementREG - Creo Medical Group - First upper GI Speedboat procedure in Europe
AnnouncementRCS - Creo Medical Group - Appointment of Marco Scarci
AnnouncementREG - Creo Medical Group - Speedboat Inject upper GI clearance in Europe
AnnouncementREG - Creo Medical Group - Speedboat™ Inject selected by NICE for assessment
Announcement